Terlipressin: A promising vasoactive agent in hemodynamic support of septic shock

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2569-2575

  Morelli, Andrea ^a   Ertmer, Christian ^b   Pietropaoli, Paolo ^a   Westphal, Martin ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Arginine vasopressin; Catecholamines; Norepinephrine; Sepsis; Septic shock; Terlipressin

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; INSULIN; LYPRESSIN; NORADRENALIN; TERLIPRESSIN; VASOPRESSIN;

ARTERIAL PRESSURE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BODY TEMPERATURE; CONTINUOUS INFUSION; CORTICOTROPIN RELEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; ESOPHAGEAL VARICES BLEEDING; FLUID BALANCE; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMICS; HEPATORENAL SYNDROME; HORMONE BLOOD LEVEL; HUMAN; HYPONATREMIA; INFORMATION RETRIEVAL; INSULIN RELEASE; ISCHEMIC SKIN NECROSIS; LIVER DYSFUNCTION; LIVER PERFUSION; LUNG VASCULAR RESISTANCE; MEDLINE; MEMORY; MESENTERY BLOOD FLOW; REVIEW; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE AGGREGATION; TISSUE EDEMA; VASOCONSTRICTION; WATER ABSORPTION;

ANIMALS; CARDIAC OUTPUT; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYSINE VASOPRESSIN; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 70349400532     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903257808     Document Type: Review

References (54)

1. Krag A, Borup T, Moller S, etal. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105-1140
2. Martin-Llahi M, Pepein MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359 (Pubitemid 351626950)
3. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64 (Pubitemid 36140434)
4. Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 2003;98:1338-1344 (Pubitemid 36622465)
5. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;23:588-595 • An exhaustive review discussing the mechanisms involved in the genesis of vasodilatory and the rationale of vasopressin administration in this type of shock.
6. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
7. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000;11:406-410
8. Maybauer MO, Maybauer DM, Enkhbaatar P, etal. Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 2008;22:253-263 • An exhaustive review discussing the physiology of the vasopressin receptors.
9. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care 2003;7:427-434
10. Barret LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40 (Pubitemid 46035674)
11. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006;40:2170-2177
12. Forsling ML, Aziz LA, Miller M, et al. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 1980;85:237-244
13. Nilsson G, Lindblom P, Ohlin M, et al. Pharmakinetics of terlipressin after single i.v. doses to healthy volunteers. Drug Exp Clin Res 1990;16:307-314
14. Lange M, Ertmer C, Westphal M. Vasopressin vs terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008;34:821-832 A very good review discussing the use of vasopressin and terlipressin in septic shock and the results of some recent trials. (Pubitemid 351571184)
15. Ryckwaert F, Virsolvy A, Fort A, et al. Terlipressin, a pro-vasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009;37:876-881
16. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125 First study reported low vasopressin levels in patients with septic shock.
17. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-1758 (Pubitemid 36714233)
18. Scharte M, Meyer J, Van Aken H, et al. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001;29:1756-1760 (Pubitemid 32848377)
19. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003;31:215-220 (Pubitemid 36151174)
20. Lange M, Morelli A, Ertmer C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007;28:623-629 (Pubitemid 350287450)
21. Westphal M, Stubbe H, Sielenkamper AW, et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003;29:301-308 (Pubitemid 36384421)
22. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-1210
23. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004;30:597-604 (Pubitemid 38530094)
24. Albanese J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005;33:1897-1902 (Pubitemid 41306507)
25. Leone M, Albanese J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004;22:314-319 (Pubitemid 39468969)
26. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-493 (Pubitemid 32225288)
27. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, etal. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 2004;30:477-480
28. Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, etal. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 2006;10:R20
29. Zeballos G, Lopez-Herce J, Fernandez C, et al. Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 2006;68:151-153 (Pubitemid 43053382)
30. Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med 2008;34:511-517 (Pubitemid 351623035)
31. Klein M, Weksler N, Borer A, et al. Terlipressin facilitates transport of septic patients treated with norepinephrine. Isr Med Assoc J 2006;8:691-693 (Pubitemid 44696906)
32. Medel J, Boccara G, Van de Steen E, et al. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg 2001;93:53-55
33. Schmitt W, Wagner-Thiessen E, Lux G. Ischemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastrenterology 1987;34:134-136 (Pubitemid 17104483)
34. Stephan F, Paillard F. Terlipressin-exacerbated hypokaliemia. Lancet 1998;351:1249-1250
35. Donnelan F, Cullen G, Hegarty JE, et al. Ischemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol 2007:64:550-552 (Pubitemid 47404308)
36. Morelli A, Tritapepe L, Rocco M, et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology 2005;102:12-19 (Pubitemid 40082834)
37. Lauzier F, Lèvy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006;32:1782-1789 (Pubitemid 44607366)
38. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008;100:494-503 (Pubitemid 351773610)
39. Patel BM, Chittok DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582 (Pubitemid 34193495)
40. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock. A prospective, randomized, controlled study. Circulation 2003;107:2313-2379
41. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887 The largest multicenter, prospective, randomized, double-blinded controlled study to date that compared vasopressin and norepinephrine in septic shock.
42. Singer M. Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol 2008;22:359-368 A very good review. (Pubitemid 351804051)
43. Rivers E, Nguyen B, Havstad S, et al. Early goal-Directed Therapy Collaborative Group: early goal-directed therapy in the treatment of severe sepsis and septic shock. N Eng J Med 2001;345:1368-1377
44. Rivers EP, Kruse JA, Jacobsen G, et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med 2007;35:2016-2024 (Pubitemid 47326436)
45. Jolley DH, De Keulenaer BL, Potter A, et al. Terlipressin infusion in catecholamine-resistant shock. Anaesth Intensive Care 2003;31:560-564
46. Morelli A, Ertmer C, Lange M, et al. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med 2007;33:1669-1670
47. Umgelter A, Reindl W, Schmid RM, et al. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Med 2008;34:390-391 (Pubitemid 351207641)
48. Morelli A, Ertmer C, Lange M, et al. Continuous terlipressin versus vasopressin infusion in septic shock: the TERLIVAP study. Crit Care 2008;12(Suppl 2):P403
49. Asfar P, Hauser B, Ivanyi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005;33:373-380 (Pubitemid 40216552)
50. Rehberg S, Ertmer C, Köhler G, etal. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009;35:1286-1296
51. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-818
52. Annane D. Vasopressin plus corticosteroids: the shock duo! Crit Care Med 2009;37:1126-1127
53. Traber D. Selective V1a receptor agonists in experimental septic shock. Crit Care 2007;11(Suppl 4):P51
54. Laporte R, Russell J, Landry D, et al. The selective V1a receptor agonist FE 202158 reverses platelet activating factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Crit Care 2008;12(Suppl 2):P407